Exelixis | EXEL - Aktuelle Verpflichtungen





Aktuelle Verpflichtungen Veränderung Datum
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Akebia Therapeutics USD 162.94M 29.56M 2025-12
Amgen USD 25.49B 3.7B 2025-12
AstraZeneca USD 32.57B 1.95B 2026-03
Bayer EUR 32.58B 3.63B 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Cytokinetics USD 202.45M 60.31M 2025-12
Eisai JPY 387.67B 9.42B 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.81M 58.22M 2025-12
Exelixis USD 405.64M 31.86M 2025-12
Genmab DKK 1.43B 686M 2025-12
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Incyte USD 1.49B 25.52M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
MacroGenics USD 43.11M 1.36M 2025-12
Merck USD 28.33B 301M 2025-12
Moderna USD 1.99B 306M 2025-12
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Novartis USD 27.28B 4.72B 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sanofi EUR 28.35B 9.32B 2025-12
Takeda JPY 2.61T 470.53B 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Xencor USD 95.91M 9.42M 2025-12